PT  - JOURNAL ARTICLE
AU  - Takuya Tada
AU  - Hao Zhou
AU  - Belinda M. Dcosta
AU  - Marie I. Samanovic
AU  - Amber Cornelius
AU  - Ramin S. Herati
AU  - Mark J. Mulligan
AU  - Nathaniel R. Landau
TI  - Neutralization of Mu and C.1.2 SARS-CoV-2 Variants by Vaccine-elicited Antibodies in Individuals With and Without Previous History of Infection
AID  - 10.1101/2021.10.19.463727
DP  - 2021 Jan 01
TA  - bioRxiv
PG  - 2021.10.19.463727
4099  - http://biorxiv.org/content/early/2021/10/20/2021.10.19.463727.short
4100  - http://biorxiv.org/content/early/2021/10/20/2021.10.19.463727.full
AB  - Recently identified SARS-CoV-2 variants Mu and C.1.2 have mutations in the receptor binding domain and N- and C-terminal domains that might confer resistance to natural and vaccine-elicited antibody. Analysis with pseudotyped lentiviruses showed that viruses with the Mu and C.1.2 spike proteins were partially resistant to neutralization by antibodies in convalescent sera and those elicited by mRNA and adenoviral vector-based vaccine-elicited antibodies. Virus with the C.1.2 variant spike, which is heavily mutated, was more neutralization-resistant than that of any of variants of concern. The resistance of the C.1.2 spike was caused by a combination of the RBD mutations N501Y, Y449H and E484K and the NTD mutations. Although Mu and C.1.2 were partially resistant to neutralizing antibody, neutralizing titers elicited by mRNA vaccination remained above what is found in convalescent sera and thus are likely to remain protective against severe disease. The neutralizing titers of sera from infection-experienced BNT162b2-vaccinated individuals, those with a history of previous SARS-CoV-2 infection, were as much as 15-fold higher than those of vaccinated individuals without previous infection and effectively neutralized all of the variants. The findings demonstrate that individuals can raise a broadly neutralizing humoral response by generating a polyclonal response to multiple spike protein epitopes that should protect against current and future variants.Competing Interest StatementThe authors declare no competing interests except M.J.M. who received research grants from Lilly, Pfizer, and Sanofi, and serves on advisory boards for Pfizer, Merck, and Meissa Vaccines.